Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine
Taweewun Hunsawong, Stefan Fernandez, Rome Buathong, Naretrit Khadthasrima, Kamonthip Rungrojchareonkit, Jindarat Lohachanakul, Rungarun Suthangkornkul, Kedsara Tayong, Angkana T. Huang, Chonticha Klungthong, Piyawan Chinnawirotpisan, Yongyuth Poolpanichupatam, Anthony R. Jones, Eric Lombardini, Supaporn Wacharapluesadee, Opass Putcharoen
Abstract
In vitro determination of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies induced in serum samples from recipients of the CoronaVac vaccine showed a short protection period against the original virus strain and limited protection against variants of concern. These data provide support for vaccine boosters, especially variants of concern circulate.
Topics & Concepts
VirologyTiterVirusNeutralizing antibodyAntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronavirusMedicineCoronavirus disease 2019 (COVID-19)BiologyImmunologyDiseaseInfectious disease (medical specialty)PathologySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesVaccine Coverage and Hesitancy